Eiry W. Roberts MD

Researchers recently found that the pharmacokinetic properties of vesicular monoamine transporter 2 inhibitors may play a role in the treatment of tardive dyskinesia.

Genetic-based screening tests among children with epilepsy may provide knowledge into the clinical characteristics of molecular diagnoses of rarer forms of the disorder, researchers found.

Neurocrine Biosciences Inc. recently presented data on comorbidities, polypharmacy and treatment patterns of patients prescribed benztropine who also were being treated with antipsychotic medications.